Cloud Banner

Healthcare

Image

Global Recombinant Polyclonal Antibodies Market – Industry Trends and Forecast to 2030

  • Healthcare
  • Upcoming Report
  • Dec 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Recombinant Polyclonal Antibodies Market, By Product Type (Primary Antibody, Secondary Antibody), Therapeutics (Cancer, Chronic Diseases), End Users (Hospitals, Research Institutes, Biopharmaceutical Companies, Contract Research Institutes, Research Laboratories), Application (Hepatitis Diagnostics, Tuberculosis Diagnostics, Cancer Diagnostics, Oncology Diagnostics, HIV Diagnostics, Infectious Disease Diagnostics, Others) – Industry Trends and Forecast to 2030.

Recombinant Polyclonal Antibodies Market

Recombinant Polyclonal Antibodies Market Analysis and Size

In the medical business and among researchers, recombinant antibodies are gaining popularity. Antibodies that have been recombinated are used in medicinal and research purposes. Recombination antibodies come in a variety of configurations that are employed in human and pharmaceutical research and development.                               

Data Bridge Market Research analyzes that the global recombinant polyclonal antibodies market, which was USD 329.23 million in 2022, would rocket up to USD 625.00 million by 2030, and is expected to undergo a CAGR of 7.70% during the forecast period. “Primary antibody” segment dominates the product type segment of the recombinant polyclonal antibodies market owing to the advancements in technology. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Product Type (Primary Antibody, Secondary Antibody), Therapeutics (Cancer, Chronic Diseases), End Users (Hospitals, Research Institutes, Biopharmaceutical Companies, Contract Research Institutes, Research Laboratories), Application (Hepatitis Diagnostics, Tuberculosis Diagnostics, Cancer Diagnostics, Oncology Diagnostics, HIV Diagnostics, Infectious Disease Diagnostics, Others)

Countries Covered

U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America

Market Players Covered

Thermo Fisher Scientific (U.S.), Abgenex (India), Bio-Rad Laboratories, Inc. (U.S.), Absolute Antibody (U.K.), GenScript (U.S.), Creative BioLabs (U.S.), Bioventix plc (U.K.)

Market Opportunities

  • Rising technological advancements
  • Increase in research activity, particularly in the life sciences industry
  • Expanding industry-academia collaborations

Market Definition

Recombinant polyclonal antibodies are a class of antibodies that are produced through a combination of recombinant DNA technology and traditional antibody generation methods. These antibodies are designed to harness the specificity and diversity of polyclonal antibodies while offering the advantages of reproducibility and consistency typically associated with monoclonal antibodies.

Recombinant Polyclonal Antibodies Market Dynamics

Drivers

  • Growing Demand for Therapeutic Antibodies

The demand for therapeutic antibodies has been steadily increasing due to their applications in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. Recombinant polyclonal antibodies have the potential to be more effective and consistent in therapeutic applications.

  • Advantages over Traditional Polyclonal Antibodies

Recombinant polyclonal antibodies offer advantages such as batch-to-batch consistency, reduced variability, and higher specificity when compared to traditional polyclonal antibodies. These benefits are driving the adoption of recombinant polyclonal antibodies in research and diagnostic applications

  • Increased Prevalence of Chronic Diseases

The prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases is on the rise globally. Recombinant polyclonal antibodies hold great potential in the development of targeted therapies for these diseases, further driving market demand.

Opportunities

  • Technological Advancements

Advances in biotechnology and recombinant DNA technology have made it easier and more cost-effective to produce recombinant polyclonal antibodies. This has led to increased commercial availability and accessibility of these antibodies.

  • Rising Investments in Research and Development

Pharmaceutical and biotechnology companies, as well as academic institutions, are investing heavily in research and development of novel biologics, including recombinant polyclonal antibodies. This is spurring innovation and acting as opportunity for market growth.

Restraints/Challenges

  • High Development Costs

Developing recombinant polyclonal antibodies can be expensive and time-consuming. The need for extensive research, optimization, and production processes can pose financial barriers for smaller biotech companies and academic institutions.

  • Complex Manufacturing Processes

The production of recombinant polyclonal antibodies involves complex manufacturing processes, which can result in production challenges and scalability issues. This complexity can hinder the commercialization and availability of these antibodies.

This recombinant polyclonal antibodies market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Recombinant Polyclonal Antibodies Market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent DevelopmentS

  • In February 2023, Roche introduced the ATRX rabbit polyclonal antibody and the IDH1 R132H (MRQ-67) rabbit monoclonal primary antibody to detect mutation status in patients with brain cancer
  • In 2019, SunRock Biopharma and GenScript have teamed up to research therapeutic antibody candidates. SunRock Biopharma will use GenScript's recombinant polyclonal antibody research, cell line development, GMP drug material process development, and drug product manufacturing capabilities

Global Recombinant Polyclonal Antibodies Market Scope

The recombinant polyclonal antibodies market is segmented on the basis of product type, therapeutics, application and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product type

  • Primary Antibody
  • Secondary Antibody

Therapeutics

  • Cancer
  • Chronic Diseases

End User  

  • Hospitals
  • Research Institutes
  • Biopharmaceutical Companies
  • Contract Research Institutes
  • Research Laboratories

Application

  • Hepatitis Diagnostics
  • Tuberculosis Diagnostics
  • Cancer Diagnostics
  • Oncology Diagnostics
  • HIV Diagnostics
  • Infectious Disease Diagnostics
  • Others

Recombinant Polyclonal Antibodies Market Regional Analysis/Insights

The recombinant polyclonal antibodies market is analysed and market size insights and trends are provided by country, product type, therapeutics, application and end user as referenced above.

The countries covered in the recombinant polyclonal antibodies market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and rest of South America as part of South America.

North America is expected to dominate the market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period due to the constant research and development.

Asia-Pacific is expected to grow during the forecast period due to technological expansion of developing countries rising expenditure on healthcare infrastructure and the emergence of unmet market demand will propel the market's growth rate in this region.

 The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The recombinant polyclonal antibodies market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for recombinant polyclonal antibodies market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the recombinant polyclonal antibodies market. The data is available for historic period 2010-2020.

Competitive Landscape and Recombinant Polyclonal Antibodies Market Share Analysis

The recombinant polyclonal antibodies market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to recombinant polyclonal antibodies market.

Some of the major players operating in the recombinant polyclonal antibodies market are:

  • Thermo Fisher Scientific (U.S.)
  • Abgenex (India)
  • Bio-Rad Laboratories, Inc. (U.S.)
  • Absolute Antibody (U.K.)
  • GenScript (U.S.)
  • Creative BioLabs (U.S.)
  • Bioventix plc (U.K.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The recombinant polyclonal antibodies market size will be worth USD 625.00 million by 2030.
The growth rate of the recombinant polyclonal antibodies market is 7.70% in the forecast by 2030.
Product type, therapeutics, application, and end-user are the factors on which the recombinant polyclonal antibodies market research is based.
Growing demand for therapeutic antibodies, advantages over traditional polyclonal antibodies &increased prevalence of chronic diseases are the growth drivers of the recombinant polyclonal antibodies market.
Major companies in the recombinant polyclonal antibodies market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials